Studies on the mechanism of the venoconstrictor activity of ergotamine on isolated canine saphenous veins.
D000818:Animals; D003042:Cocaine / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004878:Ergotamine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D005260:Female; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009638:Norepinephrine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010646:Phentolamine / Q000494:pharmacology*; D012501:Saphenous Vein / Q000187:drug effects*; D014439:Tyramine / Q000494:pharmacology*
D003042:Cocaine; D004878:Ergotamine; D009638:Norepinephrine; D014439:Tyramine; D010646:Phentolamine